Geode Capital Management
ALDX icon

Geode Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Geode Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.12M Buy
1,251,652
+81,115
+7% +$355K ﹤0.01% 3096
2025
Q4 		$6.06M Sell
1,170,537
-5,883
-0.5% -$30.2K ﹤0.01% 2669
2025
Q3 		$6.14M Buy
1,176,420
+29,823
+3% +$156K ﹤0.01% 2678
2025
Q2 		$4.39M Buy
1,146,597
+8,769
+0.8% +$22.7K ﹤0.01% 2796
2025
Q1 		$6.54M Buy
1,137,828
+18,273
+2% +$108K ﹤0.01% 2522
2024
Q4 		$5.59M Buy
1,119,555
+4,927
+0.4% +$25.3K ﹤0.01% 2691
2024
Q3 		$6.01M Sell
1,114,628
-23,415
-2% -$111K ﹤0.01% 2666
2024
Q2 		$3.77M Buy
1,138,043
+109,845
+11% +$430K ﹤0.01% 2878
2024
Q1 		$3.36M Buy
1,028,198
+5,626
+0.6% +$18.5K ﹤0.01% 2903
2023
Q4 		$3.59M Buy
1,022,572
+47,000
+5% +$145K ﹤0.01% 2865
2023
Q3 		$6.52M Buy
975,572
+22,322
+2% +$166K ﹤0.01% 2503
2023
Q2 		$8M Buy
953,250
+464,905
+95% +$4.58M ﹤0.01% 2423
2023
Q1 		$4.85M Buy
488,345
+21,768
+5% +$154K ﹤0.01% 2637
2022
Q4 		$3.25M Sell
466,577
-2,852
-0.6% -$16.3K ﹤0.01% 2869
2022
Q3 		$2.51M Sell
469,429
-17,340
-4% -$104K ﹤0.01% 3007
2022
Q2 		$1.94M Sell
486,769
-426,099
-47% -$1.47M ﹤0.01% 3122
2022
Q1 		$4.06M Buy
912,868
+60,108
+7% +$239K ﹤0.01% 2919
2021
Q4 		$3.41M Sell
852,760
-49,157
-5% -$375K ﹤0.01% 3103
2021
Q3 		$7.92M Buy
901,917
+3,400
+0.4% +$31.2K ﹤0.01% 2633
2021
Q2 		$10.2M Buy
898,517
+500,080
+126% +$6.01M ﹤0.01% 2445
2021
Q1 		$4.73M Buy
398,437
+94,932
+31% +$1.09M ﹤0.01% 2814
2020
Q4 		$2.08M Buy
303,505
+34,913
+13% +$245K ﹤0.01% 3060
2020
Q3 		$1.99M Buy
268,592
+28,994
+12% +$187K ﹤0.01% 2874
2020
Q2 		$999K Sell
239,598
-93,156
-28% -$340K ﹤0.01% 3137
2020
Q1 		$821K Buy
332,754
+3,062
+0.9% +$13.8K ﹤0.01% 3091
2019
Q4 		$1.92M Buy
329,692
+24,948
+8% +$144K ﹤0.01% 3025
2019
Q3 		$1.61M Buy
304,744
+955
+0.3% +$5.14K ﹤0.01% 3052
2019
Q2 		$1.82M Buy
303,789
+29,341
+11% +$221K ﹤0.01% 3010
2019
Q1 		$2.48M Buy
274,448
+29,056
+12% +$247K ﹤0.01% 2722
2018
Q4 		$2.04M Buy
245,392
+89,057
+57% +$913K ﹤0.01% 2763
2018
Q3 		$2.16M Buy
156,335
+8,598
+6% +$69.8K ﹤0.01% 2837
2018
Q2 		$1.17M Buy
147,737
+45,474
+44% +$363K ﹤0.01% 3116
2018
Q1 		$766K Hold
102,263
– – ﹤0.01% 3243
2017
Q4 		$695K Buy
102,263
+26,269
+35% +$173K ﹤0.01% 3239
2017
Q3 		$547K Buy
75,994
+18,140
+31% +$94.7K ﹤0.01% 3328
2017
Q2 		$271K Buy
57,854
+2,966
+5% +$13.6K ﹤0.01% 3576
2017
Q1 		$274K Buy
54,888
+1,912
+4% +$9.85K ﹤0.01% 3539
2016
Q4 		$283K Hold
52,976
– – ﹤0.01% 3478
2016
Q3 		$415K Buy
52,976
+25,999
+96% +$159K ﹤0.01% 3322
2016
Q2 		$153K Buy
26,977
+3,419
+15% +$19.1K ﹤0.01% 3672
2016
Q1 		$98 Buy
23,558
+1,000
+4% +$4.8K ﹤0.01% 3836
2015
Q4 		$152K Hold
22,558
– – ﹤0.01% 3771
2015
Q3 		$131K Hold
22,558
– – ﹤0.01% 3820
2015
Q2 		$175K Hold
22,558
– – ﹤0.01% 3628
2015
Q1 		$234K Hold
22,558
– – ﹤0.01% 3517
2014
Q4 		$162K Hold
22,558
– – ﹤0.01% 3658
2014
Q3 		$135K Buy
+22,558
New +$110K ﹤0.01% 3683

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management's ALDX Position: Q1 2026 in Review

Geode Capital Management increased its Aldeyra Therapeutics (ALDX) stake by 6.9% in Q1 2026, buying an estimated $355K and bringing the position to 1,251,652 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3096.

Geode Capital Management first reported a position in ALDX in Q3 2014 and has held it in 47 quarters since. The position peaked at $10.2M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Geode Capital Management held 1,251,652 shares of Aldeyra Therapeutics worth $2.12M as of Q1 2026.
  • Geode Capital Management bought 81,115 Aldeyra Therapeutics shares in Q1 2026, an estimated $355K.
  • Aldeyra Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3096 holding.
  • Geode Capital Management first reported a position in Aldeyra Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Geode Capital Management's Aldeyra Therapeutics position peaked at $10.2M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.